

Stefania Tommasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3428360/publications.pdf>

Version: 2024-02-01

152
papers

5,510
citations

126858

33
h-index

98753

67
g-index

156
all docs

156
docs citations

156
times ranked

11759
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
2	Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. <i>Diagnostics</i> , 2022, 12, 682.	1.3	2
3	The Impact of Mediterranean Dietary Intervention on Metabolic and Hormonal Parameters According to <i>BRCA1/2</i> Variant Type. <i>Frontiers in Genetics</i> , 2022, 13, 820878.	1.1	2
4	<i>NR1H3</i> (LXR \pm) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 864-875.	0.8	7
5	Lifestyle Characteristics in Women Carriers of <i>BRCA</i> Mutations: Results From an Italian Trial Cohort. <i>Clinical Breast Cancer</i> , 2021, 21, e168-e176.	1.1	13
6	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2227.	1.8	2
7	Prospective Observational COVID-19 Screening and Monitoring of Asymptomatic Cancer Center Health-Care Workers with a Rapid Serological Test. <i>Diagnostics</i> , 2021, 11, 975.	1.3	3
8	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7693.	1.8	6
9	A Cost Decision Model Supporting Treatment Strategy Selection in <i>BRCA1/2</i> Mutation Carriers in Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 847.	1.1	4
10	Spectrum of Germline Pathogenic Variants in <i>BRCA1/2</i> Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing. <i>Cancers</i> , 2021, 13, 4714.	1.7	3
11	A Promising Role of TGF- β 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241.	0.8	3
12	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
13	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for <i>BRCA1</i> and <i>BRCA2</i> : A systematic review and case report analysis. <i>Gynecologic Oncology</i> , 2020, 156, 377-386.	0.6	14
14	<i>BRCA1/2</i> Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers. <i>Cancers</i> , 2020, 12, 3584.	1.7	2
15	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5243.	1.8	18
16	Somatic <i>BRCA</i> Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. <i>Frontiers in Oncology</i> , 2020, 10, 1292.	1.3	2
17	miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415.	1.8	23
18	The Role of Circulating Adiponectin and SNP276G>T at <i>ADIPOQ</i> Gene in <i>BRCA</i> -mutant Women. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 301-307.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Standardization of CTC ARàV7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. <i>Prostate</i> , 2019, 79, 54-61.	1.2	20
20	KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy. <i>Cancers</i> , 2019, 11, 1145.	1.7	33
21	Exhaled breath condensate biomarkers for lung cancer. <i>Journal of Breath Research</i> , 2019, 13, 044002.	1.5	41
22	The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1559.	1.7	20
23	Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2↑. <i>Journal of Translational Medicine</i> , 2019, 17, 20.	1.8	8
24	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749.	1.7	4
25	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. <i>Scientific Reports</i> , 2019, 9, 4099.	1.6	112
26	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	0.6	7
27	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	2.0	61
28	Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced NonâSmall Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases. <i>Translational Oncology</i> , 2019, 12, 389-395.	1.7	23
29	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. <i>Breast</i> , 2018, 38, 92-97.	0.9	23
30	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 453-461.	1.5	15
31	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 608-613.	2.0	19
32	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. <i>Frontiers in Oncology</i> , 2018, 8, 583.	1.3	25
33	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	1.3	22
34	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , 2018, 18, 552.	1.1	14
35	VEGF and TWIST1 in a 16àbiomarker immunoprofile useful for prognosis of breast cancer patients. <i>International Journal of Cancer</i> , 2017, 141, 1901-1911.	2.3	10
36	Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family. <i>Oncotarget</i> , 2017, 8, 29751-29759.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	0.8	152
38	TGFbeta and miRNA regulation in familial and sporadic breast cancer. <i>Oncotarget</i> , 2017, 8, 50715-50723.	0.8	20
39	Adipokines in hereditary breast cancer patients and healthy relatives. <i>Oncotarget</i> , 2017, 8, 101255-101261.	0.8	5
40	Angiogenesis in adenosquamous cancer of pancreas. <i>Oncotarget</i> , 2017, 8, 95773-95779.	0.8	19
41	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. <i>Oncotarget</i> , 2016, 7, 25135-25149.	0.8	6
42	Next-generation sequencing: advances and applications in cancer diagnosis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7355-7365.	1.0	142
43	<i>BRCA1</i> diagnostic workflow from next-generation sequencing technologies to variant identification and final report. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 803-813.	1.5	11
44	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	13.7	1,760
45	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
46	Detrimental effects of melanocortin-1 receptor (<i>MC1R</i>) variants on the clinical outcomes of <i>BRAF</i> V600 metastatic melanoma patients treated with <i>BRAF</i> inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 679-687.	1.5	8
47	New insight into the role of metabolic reprogramming in melanoma cells harboring <i>BRAF</i> mutations. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2710-2718.	1.9	27
48	EMSY copy number variation in male breast cancers characterized for <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 181-186.	1.1	6
49	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	5.8	119
50	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016, 17, 400-406.	1.5	67
51	miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. <i>Tumor Biology</i> , 2016, 37, 5503-5513.	0.8	16
52	miR-151-5p, targeting chromatin remodeler <i>SMARCA5</i> , as a marker for the BRCAness phenotype. <i>Oncotarget</i> , 2016, 7, 80363-80372.	0.8	21
53	Somatic alterations of targetable oncogenes are frequently observed in <i>BRCA1/2</i> mutation negative male breast cancers. <i>Oncotarget</i> , 2016, 7, 74097-74106.	0.8	8
54	β -catenin interaction with <i>NHERF1</i> and <i>RASSF1A</i> methylation in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2016, 7, 67841-67850.	0.8	14

#	ARTICLE	IF	CITATIONS
55	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. <i>Oncotarget</i> , 2015, 6, 471-483.	0.8	51
56	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. <i>European Journal of Cancer</i> , 2015, 51, 2289-2295.	1.3	25
57	<i>FANCM</i>c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
58	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1027-1035.	1.5	27
59	The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	2
60	microRNAs and next generation sequencing for the prognosis of the metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, P4.	1.8	0
61	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 26.	1.8	34
62	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 433-438.	1.1	9
63	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. <i>Oncotarget</i> , 2015, 6, 27865-27879.	0.8	5
64	KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 104.	3.5	36
65	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. <i>Cell Death and Disease</i> , 2014, 5, e1076-e1076.	2.7	17
66	Genetic risk transmission in a family affected by familial breast cancer. <i>Journal of Human Genetics</i> , 2014, 59, 51-53.	1.1	4
67	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. <i>PLoS ONE</i> , 2014, 9, e112025.	1.1	15
68	Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. <i>Journal of Translational Medicine</i> , 2014, 12, 319.	1.8	9
69	MicroRNA expression profiling in male and female familial breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 2361-2368.	2.9	16
70	The value of new high-throughput technologies for diagnosis and prognosis in solid tumors. <i>Cancer Biomarkers</i> , 2014, 14, 103-117.	0.8	15
71	BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer. <i>Oncology Reports</i> , 2014, 31, 365-369.	1.2	8
72	Mitochondrial DNA variants and risk of familial breast cancer: An exploratory study. <i>International Journal of Oncology</i> , 2014, 44, 1691-1698.	1.4	33

#	ARTICLE	IF	CITATIONS
73	Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer. <i>Molecular Biotechnology</i> , 2013, 54, 913-919.	1.3	33
74	Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 861-868.	1.1	32
75	Proteomic profile in familial breast cancer patients. <i>Clinical Biochemistry</i> , 2013, 46, 259-265.	0.8	8
76	Different methylation and MicroRNA expression pattern in male and female familial breast cancer. <i>Journal of Cellular Physiology</i> , 2013, 228, 1264-1269.	2.0	34
77	HOX gene methylation status analysis in patients with hereditary breast cancer. <i>Journal of Human Genetics</i> , 2013, 58, 51-53.	1.1	30
78	<i>SULT1A1</i> gene deletion in <i>BRCA2</i> -associated male breast cancer: a link between genes and environmental exposures?. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 605-607.	1.6	8
79	Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer. <i>European Journal of Human Genetics</i> , 2013, 21, 824-830.	1.4	34
80	Mitochondria and Familial Predisposition to Breast Cancer. <i>Current Genomics</i> , 2013, 14, 195-203.	0.7	27
81	BRCA Unclassified Variants: How Can They be Classified?. <i>Current Women's Health Reviews</i> , 2012, 8, 30-37.	0.1	1
82	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 411-418.	1.1	73
83	DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families. <i>Molecular Biotechnology</i> , 2012, 52, 8-15.	1.3	22
84	Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression. <i>BMC Bioinformatics</i> , 2012, 13, S9.	1.2	39
85	Body Mass Index and Serum Proteomic Profile in Breast Cancer and Healthy Women: A Prospective Study. <i>PLoS ONE</i> , 2012, 7, e49631.	1.1	14
86	Comparison of Data-Merging Methods with SVM Attribute Selection and Classification in Breast Cancer Gene Expression. <i>Lecture Notes in Computer Science</i> , 2012, , 498-507.	1.0	5
87	Determining and Interpreting New Predictive Rules for Breast Cancer Familial Inheritance. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 125-131.	1.0	1
88	Human epidermal growth factor receptor 2, Na ⁺ /H ⁺ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. <i>Human Pathology</i> , 2011, 42, 1589-1595.	1.1	14
89	Targeting EGFR in bilio-pancreatic and liver carcinoma. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 16-22.	0.8	7
90	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. <i>European Journal of Pharmacology</i> , 2011, 670, 74-84.	1.7	10

#	ARTICLE	IF	CITATIONS
91	Mutations and polymorphic BRCA variants transmission in breast cancer familial members. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 651-657.	1.1	22
92	Gene copy number variation in male breast cancer by aCGH. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 467-473.	2.1	12
93	Oncosuppressor methylation: A possible key role in colon metastatic progression. <i>Journal of Cellular Physiology</i> , 2011, 226, 1934-1939.	2.0	20
94	Synchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver Metastasis. <i>Journal of Clinical Oncology</i> , 2011, 29, e11-e13.	0.8	8
95	Unclassified variants in BRCA genes: guidelines for interpretation. <i>Annals of Oncology</i> , 2011, 22, i18-i23.	0.6	50
96	Innovative technology for cancer risk analysis. <i>Annals of Oncology</i> , 2011, 22, i37-i43.	0.6	2
97	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1973.	3.0	7
98	Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 875-878.	1.1	11
99	Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women. <i>European Journal of Cancer Care</i> , 2010, 19, 360-368.	0.7	14
100	Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. <i>Oncology Reports</i> , 2010, 23, 1641-5.	1.2	5
101	Gene Copy Number Variation in Male Breast Cancer by aCGH. <i>Analytical Cellular Pathology</i> , 2010, 33, 113-119.	0.7	15
102	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell'€™Italia Meridionale Multicenter Phase II Study. <i>Oncology</i> , 2010, 79, 415-422.	0.9	16
103	Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 1356-1365.	1.1	12
104	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	3.4	15
105	Meeting Report: Hereditary Breast and Ovarian Cancer (HBOC): Risks and Challenges. September 10-12, 2009 Bari, Italy. <i>Breast Care</i> , 2009, 4, 347-348.	0.8	0
106	Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2694-2700.	1.1	73
107	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 565-577.	1.4	10
108	Developing optimal input design strategies in cancer systems biology with applications to microfluidic device engineering. <i>BMC Bioinformatics</i> , 2009, 10, S4.	1.2	27

#	ARTICLE	IF	CITATIONS
109	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. <i>Oncology</i> , 2009, 77, 69-74.	0.9	16
110	Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 157-164.	1.4	42
111	BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 161-167.	1.1	42
112	Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 75-83.	1.0	12
113	Molecular and in silico analysis of BRCA1 and BRCA2 variants. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 644, 64-70.	0.4	36
114	Sequencing-grade screening for BRCA1 variants by oligo-arrays. <i>Journal of Translational Medicine</i> , 2008, 6, 64.	1.8	1
115	Identification of Tumor Evolution Patterns by Means of Inductive Logic Programming. <i>Genomics, Proteomics and Bioinformatics</i> , 2008, 6, 91-97.	3.0	3
116	Exhaled breath condensate is not suitable to detect EGFR somatic mutations. <i>European Respiratory Journal</i> , 2008, 32, 1126-1127.	3.1	14
117	3p Microsatellite Signature in Exhaled Breath Condensate and Tumor Tissue of Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 337-341.	2.5	69
118	SELDI-TOF serum proteomics and breast cancer: which perspective?. <i>Expert Review of Proteomics</i> , 2008, 5, 779-785.	1.3	20
119	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. <i>International Journal of Molecular Medicine</i> , 2008, 21, 809-17.	1.8	3
120	High-Throughput Analysis of the Drug Mode of Action of PB28, MC18 and MC70, Three Cyclohexylpiperazine Derivative New Molecules. <i>Lecture Notes in Computer Science</i> , 2008, , 1085-1092.	1.0	0
121	Artificial Immune Systems in Bioinformatics. <i>Studies in Computational Intelligence</i> , 2008, , 271-295.	0.7	2
122	Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?. <i>Clinical Cancer Research</i> , 2007, 13, 5988-5990.	3.2	12
123	Induction of fuzzy rules with artificial immune systems in acgh based er status breast cancer characterization. , 2007, , .		3
124	Molecular Pathways and Related Target Therapies in Liver Carcinoma. <i>Current Pharmaceutical Design</i> , 2007, 13, 3279-3287.	0.9	68
125	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R59.	2.2	64
126	Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β -tubulins. <i>International Journal of Cancer</i> , 2007, 120, 2078-2085.	2.3	132

#	ARTICLE	IF	CITATIONS
127	Fuzzy Rule Induction and Artificial Immune Systems in Female Breast Cancer Familiarity Profiling. , 2007, , 830-837.		3
128	655Val and 1170Pro ERBB2 SNPs in Familial Breast Cancer Risk and BRCA1 Alterations. Analytical Cellular Pathology, 2007, 29, 241-248.	0.7	14
129	Altered promoter usage characterizes monoallelic transcription arising withERBB2 amplification in human breast cancers. Genes Chromosomes and Cancer, 2006, 45, 983-994.	1.5	8
130	<i>H pylori</i>status and angiogenesis factors in human gastric carcinoma. World Journal of Gastroenterology, 2006, 12, 5465.	1.4	9
131	BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 578, 395-405.	0.4	48
132	3p Microsatellite Alterations in Exhaled Breath Condensate from Patients with Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 738-744.	2.5	75
133	Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Annals of Oncology, 2005, 16, iv14-iv19.	0.6	127
134	HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast. Cancer Letters, 2005, 222, 75-81.	3.2	25
135	Genetic alterations in hereditary breast cancer. Annals of Oncology, 2004, 15, i7-i13.	0.6	45
136	Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population. Annals of Oncology, 2004, 15, i48-i54.	0.6	23
137	Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors. Clinical Cancer Research, 2004, 10, 5349-5354.	3.2	119
138	Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Letters, 2004, 209, 215-222.	3.2	19
139	ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. International Journal of Molecular Medicine, 2003, 12, 131.	1.8	7
140	ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. International Journal of Molecular Medicine, 2003, 12, 131-4.	1.8	17
141	Combination of 5-Fluorouracil and Irinotecan on Modulation of Thymidylate Synthase and Topoisomerase I Expression and Cell Cycle Regulation in Human Colon Cancer LoVo Cells: Clinical Relevance. Clinical Colorectal Cancer, 2002, 2, 182-188.	1.0	10
142	Fluorescence in situ hybridization analysis of HER-2/neu in brushings of normal oral mucosa. Cancer Genetics and Cytogenetics, 2002, 132, 141-144.	1.0	0
143	Mutations spanning P53 exons 5â€“9 detected by non-isotopic RNase cleavage assay and protein expression in human colon cancer. Cancer Genetics and Cytogenetics, 2001, 129, 40-42.	1.0	4
144	Detection of novel transcripts in the human mitochondrial DNA region coding for ATPase8-ATPase6 subunits. FEBS Letters, 1994, 344, 10-14.	1.3	13

#	ARTICLE	IF	CITATIONS
145	Sequential Alternate Administration of Tamoxifen and Medroxyprogesterone Acetate in Advanced Breast Cancer: Clinical-Biological Randomized Study. <i>Tumori</i> , 1990, 76, 190-195.	0.6	7
146	Hormone receptor modulation by a sequential alternate TAM/MPA administration monitored by drugs plasma level. <i>Pharmacological Research</i> , 1990, 22, 107-108.	3.1	1
147	Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. <i>Cancer</i> , 1989, 64, 1922-1927.	2.0	70
148	Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 31-36.	1.1	16
149	Correlation between ERICA and DCC Assay in Hormone Receptor Assessment of Human Breast Cancer. <i>Oncology</i> , 1988, 45, 308-312.	0.9	19
150	Therapeutic efficacy of various dosages and modalities of administration. <i>Inorganica Chimica Acta</i> , 1987, 137, 91-97.	1.2	4
151	Transition and transversion rate in the evolution of animal mitochondrial DNA. <i>BioSystems</i> , 1986, 19, 273-283.	0.9	33
152	Disease family history and modification of breast cancer risk in common BRCA2 variants. <i>Oncology Reports</i> , 0, , .	1.2	4